Articles That Use the Category Name:

Species and Cell Types / Virus / Influenza A


Glycomimetic Drugs - A New Source of Therapeutic Opportunities

Abstract: Carbohydrates are ubiquitous and represent the most abundant class of molecules in nature. All cell surfaces are coated with complex carbohydrates where they act as recognition molecules for other cells, functional molecules, and pathogens. Consequently, they are involved in disease indications as diverse as inflammation, cancer, and infectious disease. In general, native carbohydrates lack the properties necessary for efficacious drugs and historically have not been successful candidates to capitalize on these applications. Understanding the bioactive conformation and molecular interactions of functional carbohydrates, however, allows the rational design of small molecule glycomimetics that exhibit improved drug-like properties such as increased affinity, serum half-life, stability, and bioavailability. Recent advances in analytical techniques (i.e., NMR, x-ray crystallization), molecular modeling, and synthetic organic chemistry allow the design of potent glycomimetic compounds, which opens the door to a new class of therapeutic drugs to target molecular mechanisms that can address many of the current unmet needs in the treatment of disease. ... Read more

Book Summary: The Great Influenza -- The Epic Story of the Deadliest Plague in History

Abstract: "The Great Influenza" recounts what humanity witnessed and experienced during the 1918 influenza pandemic. Author John M. Barry also describes the remarkable transformation of U.S. medical education just prior to 1918. That transformation not only helped America cope with the pandemic but also continues to influence medical research and practice today. ... Read more

Highly Lethal H5N1 Influenza Virus in Asia: Genesis and Options for Control

Abstract: There have been violent influenza outbreaks in poultry in recent years, mostly in Asia. A small number of humans were infected, but the virus was apparently not able to be transmitted from human to human. The worry is that as the viruses keep changing their chances improve. ... Read more

Mutations, Drift, and the Influenza Archipelago

Abstract: The influenza virus genome has an uncanny ability to mutate. Changes in the genome will bring about random changes in structures of viral proteins (antigens) and hence the "antigenic drift." Physicians and scientists have been chasing them following the traces they left behind - the antibodies in the blood serum. By mapping the drift course, we may know where the antigens are headed next. ... Read more

Biotechnology/Pharmaceutical Industry News: Chiron, Iressa, and Velcade

Chiron to Purchase PowderJect, Strengthens Vaccine Franchise

On May 19, 2003, Chiron Corp., Emeryville, California announced a definitive offer to purchase PowderJect Pharmaceuticals, plc., UK for £520 or $878 million in cash. Chiron’s vaccine division had total sales of $357 million last year whereas PowderJect had total sales of $268 million in the fiscal year ending March 31, 2003.

The combination of Chiron’s vaccine business and PowderJect will become one of the top vaccine makers compared with the two companies’ existing positions as the fifth and sixth largest vaccine businesses in the world, respectively.

“We consider PowderJect to be an excellent ... Read more

Drug Profile: FluMist

Other Names: The tri-valent, cold-adapted influenza vaccine (CAIV-T).

Makers: MedImmune of Gaithersburg, MD and Wyeth of Radnor, PA.

Disease Prevented: Influenza infection caused by the influenza virus.

Chemical/Biological Nature: The influenza vaccine contains three attenuated, live, cold-adapted H1N1, H3N2, and B influenza viruses. The three vaccine virus strains are 6/2 reassortants, meaning that six genes (PB2, PB1, PA, NP, M, and NS) are derived from the cold-adapted master donor strains A/Ann Arbor/6/60 (CA-A) and B/Ann Arbor/1/66 (CA-B) and two genes for hemagglutinin (HA) and neuraminidase (NA) respectively, are derived from the circulating wild-type viruses.

Approval Status: On December 17, 2002, the U.S. ... Read more

News and Quotes: Wyeth, FluMist

Wyeth said on November 19, 2002 that it is going to discontinue the production of FluShield and Pnu-Imune, two injectable vaccines against flu and pneumonia, respectively. Instead, Wyeth is pinning its hope on FluMist, an inhaled live, attenuated flu vaccine it is co-developing with MedImmune (Gaithursburg, Maryland).

A vaccine that can be taken by inhalation would appeal to many due to the obvious ease of administration. In addition, no trained personnel are required for the administration. Collectively, the inhaled vaccine should attract more people to get vaccinated.

Wyeth and MedImmune expect FluMist will be approved in time for next year’s flu season. ... Read more

Close
Close
E-mail It